Pharmacological Inhibition of O-GlcNAcase Does Not Increase Sensitivity of Glucocorticoid Receptor-Mediated Transrepression

• Peter J. Stivers ,

  * E-mail: peter.stivers@merck.com

  Affiliation Merck & Co., Inc., Boston, Massachusetts, United States of America

  ⨯
• Lauren Harmonay,

  Affiliation Merck & Co., Inc., Boston, Massachusetts, United States of America

  ⨯
• Alexandra Hicks,

  Current address: Moderna Theraputics, Cambridge, Massachusetts, United States of America

  Affiliation Merck & Co., Inc., Boston, Massachusetts, United States of America

  ⨯
• Huseyin Mehmet,

  Current address: Proteostasis Theraputics, Cambridge, Massachusetts, United States of America

  Affiliation Merck & Co., Inc., Boston, Massachusetts, United States of America

  ⨯
• Melody Morris,

  Current address: Novartis, Cambridge, Massachusetts, United States of America

  Affiliation Merck & Co., Inc., Boston, Massachusetts, United States of America

  ⨯
• Gain M. Robinson,

  Affiliation Merck & Co., Inc., Boston, Massachusetts, United States of America

  ⨯
• Peter R. Strack,

  Current address: Celgene, Bedford, Massachusetts, United States of America

  Affiliation Merck & Co., Inc., Boston, Massachusetts, United States of America

  ⨯
• Mary J. Savage,

  Affiliation Merck & Co., Inc., Rahway, New Jersey, United States of America

  ⨯
• Dennis M. Zaller,

  Affiliation Merck & Co., Inc., Boston, Massachusetts, United States of America

  ⨯
• Izabela Zwierzynski,

  Current address: Life Technologies, Philadelphia, Pennsylvania, United States of America

  Affiliation Merck & Co., Inc., Rahway, New Jersey, United States of America

  ⨯
• Philip E. Brandish

  Affiliation Merck & Co., Inc., Boston, Massachusetts, United States of America

  ⨯